Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 22;23(1):198.
doi: 10.1186/s12957-025-03839-6.

Concurrent SMARCA4-deficient and poorly differentiated adenocarcinomas in separate lung lobes: a case report and literature review

Affiliations
Review

Concurrent SMARCA4-deficient and poorly differentiated adenocarcinomas in separate lung lobes: a case report and literature review

Lu Wang et al. World J Surg Oncol. .

Abstract

Background: SMARCA4 and SMARCA2, mutually exclusive catalytic ATPase subunits of human mammalian Switch/Sucrose-Nonfermentable chromatin remodeling enzymes, function as tumor suppressor genes. SMARCA4-deficient adenocarcinoma (SMARCA4-dADC) is a relatively rare subtype of TTF1/P40-negative non-small cell lung cancer. The concurrent presentation of SMARCA4-dADC and poorly differentiated adenocarcinoma with SMARCA2 (also known as BRM) loss in separate lobes of the same patient is even less common. This report describes such a case involving the simultaneous occurrence of these two tumor types in distinct locations within the lungs.

Case presentation: A 68-year-old male presented with a three-week history of vague pain in the right side of the chest, with no obvious trigger. Imaging revealed solid masses in the upper and lower lobes of the right lung with bilateral enlarged cervical lymph nodes. So, both of these masses underwent wedge resection. Histopathological examination confirmed that the lower lobe tumor was SMARCA4-dADC, while the upper lobe tumor was diagnosed as poorly differentiated adenocarcinoma. Although histologically similar, both exhibiting predominantly solid sheets and complex glandular structures, the two tumors displayed distinct immunohistochemical and molecular profiles. The lower lobe mass showed complete loss of BRG1 protein expression and partial loss of BRM. Immunohistochemical analysis revealed negative expression of TTF1, Napsin A, SALL4, CD34, and SOX2, and positive expression of CK7, pan-Cytokeratin (CK-pan), and HepPar-1. Molecular analysis identified mutations in SMARCA4, KRAS, and STK11. Conversely, the upper lobe mass retained BRG1 expression but showed complete loss of BRM protein expression, and negative expression of SALL4, CD34, and HepPar-1, positive expression of CK7, CK-pan, TTF1, Napsin A, and SOX2. A KRAS mutation was also detected in this tumor.

Conclusion: The simultaneous occurrence of SMARCA4-dADC and conventional adenocarcinoma in different locations within the same patient is exceedingly rare. However, the distinct immunophenotypic and molecular characteristics of SMARCA4-dADC differentiate it as a unique entity from conventional adenocarcinoma. We recommend including SMARCA4 in the marker panel used to evaluate TTF1-negative adenocarcinomas of potential or uncertain pulmonary origin. This report underscores the diagnostic challenge of concurrent SMARCA4-dADC and poorly differentiated adenocarcinoma, proposing a standardized immunohistochemical workflow to guide therapeutic decisions.

Keywords: Brahma-related gene 1 (BRG1) protein; Non-small cell lung cancers; SMARCA2; SMARCA4.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics: The research was approved by the institutional ethics review board of the Fourth Affiliated Hospital, Zhejiang University School of Medicine (K2025006) and conducted in accordance with the principles of the World Medical Association’s Declaration of Helsinki “Ethical Principles for Medical Research Involving Human Beings.” Informed consent: Written informed consent was obtained from the patient to publish this paper. Conflict of interest: The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Chest CT images of the patient. (a) CT images of the lung window with a lung mass in the right lower lobe. (b) CT images of the mediastinum window with a lung mass in the right lower lobe. (c) CT images of the lung window with a lung mass in the right upper lobe. (d) CT images of the mediastinum window with a lung mass in the right upper lobe
Fig. 2
Fig. 2
Histological analysis. (a-c) H&E staining of the right lower lung lobe mass. (d-f) H&E staining of the right upper lung lobe mass. (a, d) Solid and complex glandular regions. Scale bar:50 μm. (b, e) Necrosis regions. Scale bar:50 μm. (c, f) Red arrows: nuclear mitotic image. Scale bar:200 μm
Fig. 3
Fig. 3
Immunohistochemical staining for BRG-1, BRM, CK7, TTF1, Naspin A, CK-pan, CD34, SOX2, SALL4 and HepPar-1 in the right lung lower and upper lobe masses. Red arrows: tumor cell. Blue arrows: mesenchymal cell (internal positive control). Scale bar:100 μm
Fig. 4
Fig. 4
Molecular analysis. (a) qPCR amplification plot shows that KRAS G12D mutations were found in SMARCA4-dADC. (b) qPCR amplification plot shows that KRAS G12C mutations were found in the poorly differentiated adenocarcinoma. (c, d) Images of the reads aligned to the reference genome as provided by the Integrative Genomics Viewer. (c) The mutations SMARCA4 p.(R381*), KRAS p.(G12D), STK11 p.(K96*), BRCA1 p.(N909I), STK11 p.(R106=), and POLE p.(Y85H) were detected by NGS in the SMARCA4-dADC. (d) The mutations KRAS p.(G12C), PIK3R1 p.(R409G), STK11 p.(R106=) and BRCA1 p.(N909I) were detected by NGS in poorly differentiated adenocarcinoma

Similar articles

References

    1. Mardinian K, Adashek JJ, Botta GP, Kato S, Kurzrock R. SMARCA4: implications of an altered Chromatin-Remodeling gene for Cancer development and therapy. Mol Cancer Ther. 2021;20:2341–51. - PMC - PubMed
    1. Rekhtman N, Montecalvo J, Chang JC, Alex D, Ptashkin RN, Ai N, et al. SMARCA4-Deficient thoracic sarcomatoid tumors represent primarily Smoking-Related undifferentiated carcinomas rather than primary thoracic sarcomas. J Thorac Oncol. 2020;15:231–47. - PMC - PubMed
    1. Perret R, Chalabreysse L, Watson S, Serre I, Garcia S, Forest F, et al. SMARCA4-deficient thoracic sarcomas: clinicopathologic study of 30 cases with an emphasis on their nosology and differential diagnoses. Am J Surg Pathol. 2019;43:455–65. - PubMed
    1. Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, et al. The 2021 WHO classification of lung tumors: impact of advances since 2015. J Thorac Oncol. 2022;17:362–87. - PubMed
    1. Sun T, Gilani SM, Podany P, Harigopal M, Zhong M, Wang H. Cytomorphologic features of SMARCA4-deficient non-small cell lung carcinoma and correlation with immunohistochemical and molecular features. Cancer Cytopathol. 2022;130:620–9. - PubMed